TRMED Thor Medical ASA

0.4127USD3.990 NOK · OSL-1.48%Mkt Cap: 174.36M USDP/E: —

Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It offers thorium-228, as well as radium-224 and lead-212 to radiopharmaceutical customers. The company was incorporated in 200…

Key Statistics

Company
Market Cap174.36M USD
Enterprise Value167.42M USD
Revenue (TTM)169.52K USD
Gross Profit169.52K USD
Net Income (TTM)-6.00M USD
Revenue/Share0.0005 USD
Last Price0.4127 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees24
CountryNO
SectorHealthcare
IndustryBiotechnology
ISINNO0010597883
Valuation
P/E (Trailing)—
P/E (Forward)-72.55
PEG—
EV/EBITDA-26.92
EV/Revenue987.62
P/S1028.54
P/B3.50
EPS (TTM)-0.02 USD
EPS (Forward)-0.0057 USD
52W Range
0.360414% of range0.7364
52W High0.7364 USD
52W Low0.3604 USD
Profitability
Gross Margin100.00%
Oper. Margin-5055.10%
EBITDA Margin0.00%
Profit Margin-13214.58%
ROE-12.72%
ROA-8.19%
ROIC-14.48%
ROCE-10.47%
Growth
Revenue Growth800.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.92M USD
CapEx (TTM)7.56M USD
FCF Margin-12606.70%
FCF Yield-12.26%
Net Debt18.85M USD
Net Debt/EBITDA-3.03
Net Debt/FCF—
Balance Sheet
Debt/Equity0.38
Current Ratio2.89
Quick Ratio1.85
Book Value/Sh0.12 USD
Cash/Share0.02 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.5792 USD
Upside (mean)+40.4%
Target Range0.4344 USD – 0.7240 USD
0.4344+40.4% to mean0.7240
# Analysts2
Ownership
Shares Out.422.50M
Float204.18M
Insiders35.92%
Institutions7.22%
Technical
SMA 500.4511 (-8.5%)
SMA 2000.4828 (-14.5%)
Beta0.04
S&P 52W Chg12.00%
Avg Vol (30d)1.87M
Avg Vol (10d)1.18M
Technical Indicators
RSI (14)38.2
MACD-0.1023
MACD Signal-0.1142
MACD Hist.+0.0118
BB Upper0.4406 USD
BB Middle0.4242 USD
BB Lower0.4078 USD
BB Width7.72%
ATR (14)0.0149 USD
Vol Ratio (20d)0.37x

About Thor Medical (OSL: TRMED)

›

Thor Medical (OSL: TRMED) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 24 employees.

The shares were at 3.990 NOK on 19 November 2026, up 7.8% over 52 weeks. Its 52-week range is 3.485 NOK to 7.120 NOK: the price is 44.0% below the high and 14.5% above the low.

Its market capitalisation is 1.69B NOK.

Thor Medical reports return on equity of -12.7% and revenue up 800.0% year over year.

Its debt exceeds its cash by 182.30M NOK, a debt-to-equity ratio of 0.38. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 2 analysts cover the stock; their mean price target of 5.600 NOK is 40.4% above the current price. The next earnings report is expected on 25 February 2027.